Alumis Inc. (NASDAQ:ALMS) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Alumis Inc. (NASDAQ:ALMS) have been assigned an average rating of “Moderate Buy” from the twelve research firms that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, eight have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $40.30.

ALMS has been the subject of several recent analyst reports. Morgan Stanley restated an “overweight” rating and issued a $39.00 target price on shares of Alumis in a research report on Friday, May 15th. HC Wainwright reaffirmed a “neutral” rating and set a $25.00 price target on shares of Alumis in a report on Friday, August 14th. Guggenheim boosted their price objective on Alumis from $32.00 to $34.00 and gave the stock a “buy” rating in a research report on Friday, May 15th. Citigroup reissued a “neutral” rating on shares of Alumis in a report on Monday, August 17th. Finally, Wall Street Zen upgraded Alumis from a “strong sell” rating to a “hold” rating in a research report on Sunday, August 23rd.

Alumis Stock Performance

Shares of ALMS opened at $23.21 on Friday. The firm has a fifty day moving average of $26.57 and a 200-day moving average of $25.11. The company has a market cap of $3.00 billion, a price-to-earnings ratio of -6.01 and a beta of -0.69. Alumis has a 1 year low of $3.76 and a 1 year high of $31.35.

Alumis (NASDAQ:ALMS) last released its quarterly earnings data on Thursday, August 13th. The company reported ($1.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.34). The firm had revenue of $1.66 million during the quarter, compared to analyst estimates of $3.65 million. Alumis had a negative return on equity of 93.15% and a negative net margin of 5,933.46%. Analysts predict that Alumis will post -2.95 EPS for the current year.

Insider Activity at Alumis

In other Alumis news, CFO John R. Schroer sold 3,282 shares of the business’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $26.37, for a total transaction of $86,546.34. Following the completion of the transaction, the chief financial officer owned 24,718 shares in the company, valued at approximately $651,813.66. The trade was a 11.72% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Sanam Pangali sold 5,000 shares of the stock in a transaction on Monday, July 6th. The stock was sold at an average price of $28.00, for a total value of $140,000.00. Following the completion of the transaction, the insider directly owned 11,111 shares of the company’s stock, valued at approximately $311,108. The trade was a 31.03% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 19,953 shares of company stock worth $534,311 in the last ninety days. 33.70% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Alumis

Several institutional investors have recently bought and sold shares of ALMS. BlackRock Inc. bought a new position in Alumis in the 2nd quarter valued at about $231,259,000. Samsara Biocapital LLC increased its stake in Alumis by 19.9% during the 4th quarter. Samsara Biocapital LLC now owns 5,756,984 shares of the company’s stock valued at $56,188,000 after buying an additional 955,614 shares during the period. venBio Partners LLC bought a new stake in shares of Alumis during the 2nd quarter worth about $127,429,401,000. Vanguard Group Inc. raised its position in shares of Alumis by 18.4% during the 3rd quarter. Vanguard Group Inc. now owns 4,029,615 shares of the company’s stock worth $16,078,000 after buying an additional 625,404 shares in the last quarter. Finally, Cormorant Asset Management LP raised its position in shares of Alumis by 69.3% during the 4th quarter. Cormorant Asset Management LP now owns 3,635,596 shares of the company’s stock worth $35,483,000 after buying an additional 1,488,200 shares in the last quarter.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.